NANOIDROPS
Nucleic acid nanoparticles for topical ophthalmic drug delivery
| Coordinatore | RIJKSUNIVERSITEIT GRONINGEN
Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie. |
| Nazionalità Coordinatore | Netherlands [NL] |
| Totale costo | 168˙224 € |
| EC contributo | 150˙000 € |
| Programma | FP7-IDEAS-ERC
Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | ERC-2013-PoC |
| Funding Scheme | CSA-SA(POC) |
| Anno di inizio | 2014 |
| Periodo (anno-mese-giorno) | 2014-02-01 - 2015-01-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
RIJKSUNIVERSITEIT GRONINGEN
Organization address
address: Broerstraat 5 contact info |
NL (GRONINGEN) | hostInstitution | 150˙000.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Treatment of eye diseases is severely hindered by the tear fluid and eye lid movement removing the drug. As a consequence, very frequent administration of highly concentrated eye drops is necessary, causing substantial side effects. These side effects occur very often and can range from simple irritations to life threatening anaphylactic shocks in extreme cases. The other shortcoming in treating eye-related diseases is poor compliance, due to frequent dosing. We have developed a drug carrier system for eye drops that have high affinity to the cornea. This allows for a drastically lower concentration of the active compound and less frequent administration. A lower regime results in a better compliance, a higher effectiveness of the drug and less side effects. These nanoparticles can be combined with a wide variety of ophthalmic drugs, including the ones that have been abandoned due to severe side effects. Our approach has been proven during preclinical studies in rat models and even human tissue using two nanoparticle-antibiotic combinations that have shown exceptionally long lasting survival times on the eye of up to four hours. In this project we would like to complete our set of preclinical data regarding efficacy, scope and toxicity of the carrier to achieve commercialization of the drug delivery system.'